CPL976 / Celon Pharma - LARVOL DELTA

A first-in-class bispecific antibody CPL976 with a dual PD-L1/AXL mechanism of action that promotes common biological antitumor effects in in vitro and in vivo models (AACR 2024) - "CPL976 is the bispecific antibody that combines the effects of cancer inhibition by interacting with AXL and immunotherapy by disrupting the PD-1/PD-L1 axis. The use of the bispecific antibodies simultaneously targeting PD-L1 and AXL provokes internalization of the targets to maximize the biological effect of the inhibition of the receptor/ligand complexes (AXL/cGAS6, PD-1/PD-L1) formation. Simultaneous action on both therapeutic targets may help achieve an enhanced immune response against cancer cells and lead to tumor eradication and overcoming the primary and secondary resistance to PD-1/PD-L1 targeted therapies."

IO biomarker • Preclinical • Oncology • AXL • CD4 • CD8 • GAS6 • PD-L1

Development of an innovative bifunctional CPL976-MMAE conjugate based on a bispecific anti-PD-L1/ ant-AXL antibody with a dual mechanism of action (AACR 2024) - "We presented a new, ADC based on bispecific anti-PD-L1/anti-AXL antibody conjugated with MMAE, that combines the effects of cancer growth inhibition by interaction with AXL and immunotherapy by disruption of the PD-1/PD-L1 axis, with selective delivery of MMAE to cancer cells. The simultaneous action of delivering the toxin and acting on both therapeutic targets provides a potent synergistic anti-tumor effect, that can lead to complete tumor eradication and potentially overcome the primary and secondary resistance to PD-1/PD-L1 targeted therapies."

IO biomarker • Oncology • AXL

Celon Pharma presents innovative bispecific antibody CPL-976 (Bioworld) - "Data regarding an innovative bispecific antibody – CPL-976 (CPBT-0976) – were recently reported by Celon Pharma SA. Bispecific antibodies targeting more than one antigen on cancer cells improve the specificity and effectiveness of the therapy, and could be utilized for targeting the defense mechanisms of cancer cells, such PD-L1 or EGFR, VEGFR and AXL."

Preclinical • Oncology